Shots:

• The P-III (BRIGHTE) study evaluating fostemsavir + OBT in 371 heavily-experienced adults with multidrug-resistant HIV-1 inf. at 113 sites across 22 countries
• The results showed that patients treated with fostemsavir-based regimens experienced durable virologic responses for 5yrs. In the randomized cohort, 45% of patients achieved virologic suppression, 78% had a change in CD4+ cell count from <200 to ≥200 cells/mm3, and 67% had a change from <20 to ≥200 cells/mm, CD4+/CD8+ ratio also increased steadily from baseline. The safety profile was consistent with prior findings across both cohorts with no new trends in the safety data
• Additionally, 95% experienced 1 AE; 45% in SAE & 4 patients discontinued treatment due to AE @96wk. & 240wk.

Ref: ViiV Healthcare | Image: ViiV Healthcare